|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ClC-3 was highly expressed in the P-glycoprotein (P-gp)-dependent human lung adenocarcinoma cell line (A549)/paclitaxel (PTX) and the human breast carcinoma cell line (MCF-7)/doxorubicin (DOX) resistant cells.
|
30230544 |
2019 |
|
Adult Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A total of 14 clones could be matched to known genes and were categorized into four groups: A) transcription factors: prothymosin, CA150, p78 serine/threonine kinase, IL-1beta-stimulating gene, glucocorticoid receptor, MLN64/CAB1, gastrin-binding protein, and polypeptide from glioblastoma; B) chaperone: 90 kDa heat shock protein; C) ion channel: chloride channel protein 3; and D) cytoskeleton: cytovillin2/ezrin and vimentin.
|
11146166 |
2000 |
|
Adult Neuronal Ceroid Lipofuscinosis
|
0.200 |
Biomarker
|
disease |
MGD |
CLC-3 deficiency leads to phenotypes similar to human neuronal ceroid lipofuscinosis.
|
12059962 |
2002 |
|
Adult Neuronal Ceroid Lipofuscinosis
|
0.200 |
Biomarker
|
disease |
MGD |
ClC-3 chloride channels facilitate endosomal acidification and chloride accumulation.
|
15504734 |
2005 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we define the following intracellular mechanisms regulated by 1,25D3 that are associated with recovery of phagocytosis and consistent with the selectivity of BDC: 1) 1,25D3 potentiates a 4,4-diisothiocyanostilbene-2,2-disulfonic acid-sensitive chloride channel (i.e., ClC-3) currents in both Type I and II AD macrophages, but curcumin only potentiates the currents in Type I cells; 2) 1,25D3 is particularly effective in upregulating ClC-3 mRNA expression in Type II peripheral blood mononuclear cells (PBMCs) while both 1,25D3 and the BDC analog, C180, upregulate VDR mRNA, repressed by Aβ42 in Type II PBMCs; and 3) 1,25D3-induced Aβ42 phagocytosis is attenuated by the calcium-dependent ClC-3 blocker, inositol 3,4,5,6-tetraphosphate (IP4), in both AD Types and by the MEK1/2 inhibitor U0126 only in Type II macrophages.
|
22207005 |
2012 |
|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we define the following intracellular mechanisms regulated by 1,25D3 that are associated with recovery of phagocytosis and consistent with the selectivity of BDC: 1) 1,25D3 potentiates a 4,4-diisothiocyanostilbene-2,2-disulfonic acid-sensitive chloride channel (i.e., ClC-3) currents in both Type I and II AD macrophages, but curcumin only potentiates the currents in Type I cells; 2) 1,25D3 is particularly effective in upregulating ClC-3 mRNA expression in Type II peripheral blood mononuclear cells (PBMCs) while both 1,25D3 and the BDC analog, C180, upregulate VDR mRNA, repressed by Aβ42 in Type II PBMCs; and 3) 1,25D3-induced Aβ42 phagocytosis is attenuated by the calcium-dependent ClC-3 blocker, inositol 3,4,5,6-tetraphosphate (IP4), in both AD Types and by the MEK1/2 inhibitor U0126 only in Type II macrophages.
|
22207005 |
2012 |
|
Asthenozoospermia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Spermatozoa from men with asthenozoospermia demonstrated lower volume regulating capacity, mobility, and ClC-3 expression levels (especially in the neck) than did normal spermatozoa.
|
27270342 |
2018 |
|
Blindness
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Together with developmental retardation and higher mortality, the Clcn3-/- mice showed neurological manifestations such as blindness, motor coordination deficit, and spontaneous hyperlocomotion.
|
12059962 |
2002 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The aim of the present study is to explore the molecular mechanisms underlying the antitumor effect of silencing ClC-3 in breast cancer.
|
29963105 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Pharmacological modulation of ClC-3 may provide a deep understanding in antiestrogen treatment of breast cancer patients.
|
28419445 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
To assess the roles of CLCN3 in breast cancer, we next performed three-dimensional (3D) spheroid proliferation analyses using MCF10A-ErbB2 cells treated with MCF10A-neo-derived exosomes or CLCN3 shRNA stably expressing SKBR3 and MDA-MB-453 breast cancer cells.
|
31608175 |
2019 |
|
Breast Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
ClC-3 was highly expressed in the P-glycoprotein (P-gp)-dependent human lung adenocarcinoma cell line (A549)/paclitaxel (PTX) and the human breast carcinoma cell line (MCF-7)/doxorubicin (DOX) resistant cells.
|
30230544 |
2019 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In the present study, we showed the involvement of intracellular organelle ClC-3 Cl<sup>-</sup> /H<sup>+</sup> transporter in HER2 transcription in breast cancer MDA-MB-453 cells.
|
29949674 |
2018 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Chloride channel 3 (CIC-3) has been suggested to be implicated in the carcinogenesis though; it still remains ill understood in hepatocarcinoma, especially in terms of clinicopathological meaning of its expression.
|
30678806 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
ClC-3 is a type of chloride channel that has multiple functions in tumorigenesis and tumor growth, and can be blocked by DIDS (4,4'-diisothiocyanostilbene-2,2'-disulfonic acid).
|
29749557 |
2018 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The ClC-3 chloride channels in cardiovascular disease.
|
21602838 |
2011 |
|
Cervical Squamous Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ClC-3 mRNA and protein expression in SCC tissues from cervical squamous cell carcinoma patients was significantly upregulated, and no significant difference was noted between the matched paracarcinoma fresh tissue from the same patients and non-cervical cancer patients.
|
30905432 |
2019 |
|
Cervix carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this research, we explore the ClC-3 expression in cervical carcinoma and its underlying clinical significance, trying to illuminate ClC-3 probable function in the neoplasm malignant behavior, development and prognosis.
|
30636929 |
2019 |
|
Child Development Disorders, Pervasive
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.
|
28540026 |
2017 |
|
Childhood Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A total of 14 clones could be matched to known genes and were categorized into four groups: A) transcription factors: prothymosin, CA150, p78 serine/threonine kinase, IL-1beta-stimulating gene, glucocorticoid receptor, MLN64/CAB1, gastrin-binding protein, and polypeptide from glioblastoma; B) chaperone: 90 kDa heat shock protein; C) ion channel: chloride channel protein 3; and D) cytoskeleton: cytovillin2/ezrin and vimentin.
|
11146166 |
2000 |
|
Chondrosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RESULTS Results showed that the expression of ClC-3 chloride channel in the normal chondrocyte was thinner, since it showed distinct differentiation among chondrosarcoma specimens.
|
31281178 |
2019 |
|
Chorea
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Considering that chorea in this patient might be due to the disruption of a gene at either of the 4p15.32 or 4q33 breakpoints, CLCN3 was considered as a candidate gene.
|
9521585 |
1998 |
|
Cognition Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
TGF-beta/TGF-beta RII/CLC-3 axis promotes cognitive disorders in diabetes.
|
30468668 |
2019 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review will highlight the major findings and recent advances in the study of ClC-3 Cl(-) channels in the cardiovascular system and discuss their important roles in cardiac and vascular remodeling during hypertension, myocardial hypertrophy, ischemia/reperfusion, and heart failure.
|
21602838 |
2011 |
|
Developmental delay (disorder)
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Together with developmental retardation and higher mortality, the Clcn3-/- mice showed neurological manifestations such as blindness, motor coordination deficit, and spontaneous hyperlocomotion.
|
12059962 |
2002 |